Benefits no longer outweigh risks from starch IV drips, says EMA
The benefits of infusion solutions containing hydroxyethyl-starch (HES) no longer outweigh their risks, according to European regulators.
Get unlimited access
As a subscriber you will benefit from:
- Full online and mobile access to news and opinion stories
- Customised email alerts straight to your inbox (30+ alerts available)
- 4,500 practice articles in our archive
- Over £500 worth of CPD learning units